-
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)
Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
Turning Tumors Against Themselves: In Vivo Reprogramming of Cancer Cells into Dendritic Sentinels(Post)Imagine a future where cancer cells, once masters of disguise, are forced to reveal themselves and even train the body's immune system to fight back. This isn't science fiction; it's the groundbreaki
Physiological Roles for IL-33 | Assay Genie(Post)By Charlotte O'Donnell PhD A role for IL-33 in Barrier Function and Epithelial Wound Healing
Unconventional T Cells: Already Armed, and No MHC Required(Post)Most immunology is written as though a T cell must first be told what to look for. Three lineages did not read that memo. γδ T cells, invariant NKT cells and MAIT cells leave the thymus with their ef
Pathological functions of IL-33/ST2 in IBD and Cancer(Post)By Charlotte O'Donnell PhD < As IL-33/ST2 is such a potent inducer of inflammation, it is not surprising that dysr
Comment choisir une protéine cytokine pour votre étude(Post)Comment choisir une protéine cytokine pour votre étude Pour une mesure fonctionnelle in vitro, privilégiez une cytokine recombinante à activité biologique validée sur la lignée cible. Pour une admini
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies(Post)1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive compon
Guselkumab: Advancing Psoriasis and Autoimmune Disease Research Through IL-23 Targeting(Post)Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammator
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
PharmaGenie ELISA キット(Page)PharmaGenie ELISA キット | Assay Genie | Assay Genie
Pinatuzumab: Advancing Cancer Research and Therapeutics(Post)Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including non
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
Immunohistochemical Staining, Antibodies & Buffers(Page) Trauma Immunology(Post)Traumatic injuries & death When I ask people what the leading cause of death is in the United States in people age 44 and under, they generally reply saying
Agarose vs Polyacrylamide: A Comparative Analysis(Post)Techniques · Gel ElectrophoresisAgarose vs Polyacrylamide: A Comparative AnalysisAgarose and polyacrylamide are the two workhorse gel matrices of electrophoresis. Agarose gels resolve larger DNA and R
Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy(Post)What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod
Brodalumab: A Breakthrough in IL-17 Receptor Blockade for Psoriasis and Beyond(Post)Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor
Androgenic steroid action in breast cancer(Post)By Rachel Bleach, PhD Student, RCSI By the age of 79 years, 1 in 14 women will develop breast cancer (Global Burden of Disease Cancer 2017). Beatson reported
Fibroblast Markers(Post)Fibroblasts, essential components of connective tissues, play vital roles in maintaining tissue structure and function. Their remarkable ability to produce and organize the extracellular matrix
Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics(Post)What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What